Nebivolol's Almost Approvable Letter

The pharmaceutical industry is a tough industry to invest in. You can read the clinical trial data from a scientific journal, make the right call about the FDA liking the efficacy data, and still be wrong about whether the FDA approves the drug.

Unfortunately, that's what happened to fellow Fool Billy Fisher. He correctly predicted that the FDA would like the data in Forest Laboratories' (NYSE: FRX  ) and Mylan's (NYSE: MYL  ) response to the agency's previously issued approvable letter for nebivolol. But he couldn't have known that the FDA would issue another approvable letter because of deficiencies in the backup manufacturing facility in Belgium.

The companies didn't give a time frame for responding to the approvable letter, but since there weren't any issues with efficacy or safety, the response should be up much quicker than the last. Forest is continuing with its plans to have a launch meeting next month, and the companies have even agreed with the FDA on labeling text, which is usually a good sign that an approval shouldn't be too far off.

Once the issues are resolved, Forest can begin marketing nebivolol under its branded name, Bystolic. Mylan, which licensed the drug from Johnson & Johnson's (NYSE: JNJ  ) Janssen subsidiary, has the right to co-promote the drug, although it may be a little busy with integration issues to deal with a new drug launch.

The drug will join a crowded marketplace of beta blockers, including Wyeth's (NYSE: WYE  ) Inderal and GlaxoSmithKline's (NYSE: GSK  ) Coreg. With both of these drugs experiencing generic competition, Forest's sales reps could experience some heartache if doctors shun Bystolic in favor of cheaper generic drugs for their patients.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 545133, ~/Articles/ArticleHandler.aspx, 10/26/2016 10:53:52 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 hour ago Sponsored by:
DOW 18,199.33 30.06 0.17%
S&P 500 2,139.43 -3.73 -0.17%
NASD 5,250.27 -33.13 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
FRX.DL $0.00 Down +0.00 +0.00%
Forest Laboratorie… CAPS Rating: ****
MYL $38.08 Down -0.60 -1.55%
Mylan CAPS Rating: ***
GSK $40.34 Up +0.02 +0.05%
GlaxoSmithKline CAPS Rating: ***
JNJ $114.56 Up +0.60 +0.53%
Johnson and Johnso… CAPS Rating: ****
WYE.DL $0.00 Down +0.00 +0.00%
Wyeth CAPS Rating: ***